Legacy Financial Advisors Inc. Makes New $1.93 Million Investment in Novartis AG $NVS

Legacy Financial Advisors Inc. bought a new stake in Novartis AG (NYSE:NVS) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 15,061 shares of the company’s stock, valued at approximately $1,931,000.

Other hedge funds have also modified their holdings of the company. Fisher Asset Management LLC boosted its stake in Novartis by 5.3% during the second quarter. Fisher Asset Management LLC now owns 7,121,414 shares of the company’s stock worth $861,762,000 after buying an additional 358,282 shares during the period. Loomis Sayles & Co. L P boosted its position in shares of Novartis by 1.4% during the 2nd quarter. Loomis Sayles & Co. L P now owns 5,581,576 shares of the company’s stock worth $675,427,000 after purchasing an additional 78,483 shares during the period. Envestnet Asset Management Inc. increased its holdings in Novartis by 4.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 1,819,260 shares of the company’s stock valued at $233,302,000 after purchasing an additional 82,369 shares during the last quarter. State Street Corp raised its position in Novartis by 0.8% in the second quarter. State Street Corp now owns 1,597,830 shares of the company’s stock valued at $195,552,000 after purchasing an additional 12,345 shares during the period. Finally, Raymond James Financial Inc. lifted its stake in Novartis by 3.5% during the second quarter. Raymond James Financial Inc. now owns 927,314 shares of the company’s stock worth $112,214,000 after purchasing an additional 30,950 shares in the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NVS. Jefferies Financial Group reiterated a “hold” rating on shares of Novartis in a report on Monday, October 27th. HC Wainwright lowered shares of Novartis to a “neutral” rating in a research note on Monday, October 27th. Citigroup reaffirmed a “buy” rating on shares of Novartis in a research note on Thursday, February 5th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Novartis in a research note on Thursday, February 12th. Finally, JPMorgan Chase & Co. upgraded Novartis from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $119.75.

Trending Headlines about Novartis

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: President Trump said he met Novartis CEO Vas Narasimhan and highlighted the company is building 11 U.S. manufacturing plants — a signal of stronger U.S. production footprint, potential government support and on‑shoring that can reduce supply risk and support future sales. Trump meets Novartis CEO, says drugmaker building 11 US plants
• Positive Sentiment: Novartis is making a major R&D/portfolio bet — a $1.8 billion investment in oral peptide programs — which could expand its pipeline into high‑value modalities if clinical progress continues. This is growth‑oriented spending that investors may view positively for long‑term upside. Novartis Makes $1.8 Billion Bet On Oral Peptides
• Neutral Sentiment: Novartis agreed to sell its ~70.7% holding in its listed Indian unit to a consortium (WaveRise, ChrysCapital, Two Infinity) for about $159M — a sizeable strategic divestment geographically but small relative to Novartis’ market cap; it reduces direct India exposure and will free up capital, though near‑term earnings impact is modest. Novartis to sell entire 71% stake in Indian unit to consortium of WaveRise Investments
• Negative Sentiment: Analyst revisions from Zacks are mixed but tilted downward overall: Zacks issued multiple cuts to quarterly and FY2026/2027 EPS estimates (several Q2/Q3 and FY reductions), which can pressure sentiment and imply lower near‑term earnings growth expectations. These downgrades are likely the primary short‑term negative driver.
• Neutral Sentiment: Market commentary pieces (e.g., Yahoo Finance stock look) provide broader context but contain no single catalyst; useful for long‑term perspective but not a direct price driver today. Where is Novartis AG (NVS) Headed?

Novartis Price Performance

NVS stock opened at $162.76 on Monday. The business has a 50 day moving average price of $146.79 and a 200 day moving average price of $134.23. The company has a quick ratio of 0.89, a current ratio of 1.12 and a debt-to-equity ratio of 0.60. The stock has a market cap of $343.81 billion, a price-to-earnings ratio of 22.73, a PEG ratio of 2.48 and a beta of 0.50. Novartis AG has a fifty-two week low of $97.71 and a fifty-two week high of $167.86.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.04. Novartis had a net margin of 25.65% and a return on equity of 40.53%. The business had revenue of $13.86 billion during the quarter, compared to the consensus estimate of $13.85 billion. During the same quarter in the previous year, the firm earned $1.98 EPS. The company’s revenue was up 1.4% compared to the same quarter last year. Equities research analysts anticipate that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Novartis Dividend Announcement

The company also recently announced an annual dividend, which will be paid on Monday, March 16th. Stockholders of record on Wednesday, March 11th will be given a dividend of $4.773 per share. The ex-dividend date is Wednesday, March 11th. This represents a dividend yield of 312.0%. Novartis’s payout ratio is 36.31%.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.